✦ LIBER ✦

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia

✍ Scribed by Jimenez-Zepeda, Victor H.; Reece, Donna E.; Trudel, Suzanne; Chen, Christine; Tiedemann, Rodger; Kukreti, Vishal

Book ID: 127279033
Publisher: Informa plc
Year: 2014
Tongue: English
Weight: 142 KB
Volume: 56
Category: Article
ISSN: 1042-8194
DOI: 10.3109/10428194.2014.893304

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effectiveness of lenalidomide (Revlimid)

Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia

✍ Benson, Don M.; Smith, Megan K. 📂 Article 📅 2007 🏛 Informa plc 🌐 English ⚖ 165 KB

Efficacy of bortezomib, lenalidomide and

Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia

✍ Alessandro Gozzetti; Pellegrino Musto; Marzia Defina; Fiorella D'Auria; Giulia P 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Response of primary plasma cell leukemia

Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: Do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?

✍ Eirini Katodritou; Evgenia Verrou; Vassiliki Gastari; Christina Hadjiaggelidou; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 84 KB

Efficacy and safety of bortezomib in pat

Efficacy and safety of bortezomib in patients with plasma cell leukemia

✍ Pellegrino Musto; Fausto Rossini; Francesca Gay; Vincenzo Pitini; Tommasina Gugl 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 1 views

## Abstract ## BACKGROUND. The prognosis of patients with plasma cell leukemia (PCL), an aggressive variant of multiple myeloma (MM), is usually poor. Bortezomib is the first proteasome inhibitor approved for the treatment of advanced MM. Currently available information regarding the role of borte

Intermediate doses of melphalan and dexa

Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia

✍ J. Vela-Ojeda; M. García-Ruiz Esparza; A. Rosas-Cabral; Y. Padilla-González; J. 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 62 KB

Phase II study of single-agent bortezomi

Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia

✍ Stefan Faderl; Kanti Rai; John Gribben; John C. Byrd; Ian W. Flinn; Susan O'Brie 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB 👁 1 views